Brighton Jones LLC’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.16M Buy
+7,581
New +$1.16M 0.03% 422
2025
Q4
Sell
-6,679
Closed -$857K 656
2025
Q3
$857K Buy
6,679
+677
+11% +$82.6K 0.02% 446
2025
Q2
$726K Sell
6,002
-5
-0.1% -$564 0.02% 409
2025
Q1
$670K Sell
6,007
-146
-2% -$15.5K 0.02% 322
2024
Q4
$599K Buy
6,153
+2,666
+76% +$284K 0.02% 351
2024
Q3
$401K Sell
3,487
-1,912
-35% -$217K 0.02% 364
2024
Q2
$575K Buy
5,399
+495
+10% +$49.7K 0.02% 326
2024
Q1
$474K Buy
4,904
+251
+5% +$25.7K 0.02% 358
2023
Q4
$470K Buy
4,653
+7
+0.2% +$676 0.02% 334
2023
Q3
$473K Buy
4,646
+129
+3% +$13.1K 0.02% 300
2023
Q2
$456K Buy
4,517
+414
+10% +$41.4K 0.02% 309
2023
Q1
$377K Buy
4,103
+46
+1% +$4.02K 0.02% 338
2022
Q4
$368K Sell
4,057
-955
-19% -$80.4K 0.02% 294
2022
Q3
$381K Buy
5,012
+394
+9% +$32.7K 0.02% 287
2022
Q2
$390K Sell
4,618
-480
-9% -$42.1K 0.02% 290
2022
Q1
$447K Buy
5,098
+61
+1% +$5.28K 0.02% 296
2021
Q4
$441K Sell
5,037
-212
-4% -$17.6K 0.02% 303
2021
Q3
$429K Buy
5,249
+1,164
+28% +$105K 0.02% 297
2021
Q2
$373K Buy
4,085
+269
+7% +$24K 0.02% 305
2021
Q1
$326K Sell
3,816
-230
-6% -$20.6K 0.02% 298
2020
Q4
$382K Buy
4,046
+32
+0.8% +$2.8K 0.02% 254
2020
Q3
$349K Buy
4,014
+1,610
+67% +$139K 0.02% 234
2020
Q2
$210K Sell
2,404
-1,087
-31% -$93.8K 0.02% 271
2020
Q1
$288K Buy
3,491
+148
+4% +$13.2K 0.03% 217
2019
Q4
$317K Buy
3,343
+324
+11% +$29.1K 0.03% 232
2019
Q3
$262K Sell
3,019
-19
-0.6% -$1.71K 0.03% 246
2019
Q2
$277K Sell
3,038
-1,058
-26% -$89.5K 0.03% 236
2019
Q1
$353K Buy
4,096
+656
+19% +$52.7K 0.04% 208
2018
Q4
$264K Sell
3,440
-21
-0.6% -$1.64K 0.04% 208
2018
Q3
$267K Sell
3,461
-15
-0.4% -$1.11K 0.03% 218
2018
Q2
$235K Sell
3,476
-258
-7% -$17.8K 0.03% 264
2018
Q1
$271K Sell
3,734
-69
-2% -$5.25K 0.04% 229
2017
Q4
$286K Buy
3,803
+376
+11% +$28.4K 0.03% 224
2017
Q3
$264K Sell
3,427
-86
-2% -$6.5K 0.03% 226
2017
Q2
$263K Buy
+3,513
New +$249K 0.04% 209
2016
Q4
Sell
-3,878
Closed -$274K 172
2016
Q3
$274K Buy
3,878
+5
+0.1% +$364 0.04% 191
2016
Q2
$286K Buy
3,873
+630
+19% +$43.5K 0.05% 161
2016
Q1
$211K Buy
+3,243
New +$221K 0.04% 192
2015
Q3
Sell
-2,793
Closed -$246K 206
2015
Q2
$246K Buy
2,793
+18
+0.6% +$1.65K 0.06% 160
2015
Q1
$245K Buy
2,775
+55
+2% +$4.88K 0.06% 161
2014
Q4
$226K Sell
2,720
-249
-8% -$20.6K 0.05% 172
2014
Q3
$250K Sell
2,969
-68
-2% -$5.5K 0.06% 169
2014
Q2
$246K Sell
3,037
-467
-13% -$36.7K 0.06% 161
2014
Q1
$267K Buy
+3,504
New +$255K 0.06% 147
2013
Q3
Sell
-3,842
Closed -$243K 175
2013
Q2
$243K Buy
+3,842
New +$250K 0.07% 103

Other funds holding NVS

Brighton Jones LLC's NVS Position: Q1 2026 in Review

Brighton Jones LLC opened a new position in Novartis (NVS) in Q1 2026: 7,581 shares worth $1.16M. The stake represents 0.03% of the portfolio and ranks #422 among its holdings. This is a return to the name: Brighton Jones LLC previously reported a position in NVS as recently as Q3 2025.

Brighton Jones LLC first reported a position in NVS in Q2 2013 and has held it in 45 quarters since. 1,596 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Brighton Jones LLC held 7,581 shares of Novartis worth $1.16M as of Q1 2026.
  • Novartis was a new Brighton Jones LLC position in Q1 2026.
  • Novartis made up 0.03% of Brighton Jones LLC's portfolio in Q1 2026, its #422 holding.
  • Brighton Jones LLC first reported a position in Novartis in Q2 2013 and has held it in 45 quarters since.
  • 1,596 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Brighton Jones LLC's 13F filing for Q1 2026, filed 28 Apr 2026.